(Q38852405)

7 September 2017

1 reference

title

Endometrial cancer: Not your grandmother's cancer (English)

1 reference

7 September 2017

1 reference

Jessica N McAlpine

1

1 reference

7 September 2017

Sarah M Temkin

series ordinal

2

1 reference

7 September 2017

Helen J Mackay

series ordinal

3

1 reference

7 September 2017

language of work or name

English

0 references

publication date

16 June 2016

1 reference

7 September 2017

number of pages

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

7 September 2017

volume

122

1 reference

7 September 2017

issue

18

1 reference

7 September 2017

page(s)

2787-2798

1 reference

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Prediction of cancer incidence and mortality in Korea, 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Global burden of cancer attributable to high body-mass index in 2012: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Recent changes in endometrial cancer trends among menopausal-age U.S. women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

USA endometrial cancer projections to 2030: should we be concerned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Body mass index and the quality of life of endometrial cancer survivors--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

A systematic review and meta-analysis of physical activity and endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Mechanisms linking physical activity with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

PI3K signaling in the pathogenesis of obesity: The cause and the cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Impact of Obesity on Surgical Treatment for Endometrial Cancer: A Multicenter Study Comparing Laparoscopy vs Open Surgery, with Propensity-Matched Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

The impact of obesity on the 30-day morbidity and mortality after surgery for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

The impact of BMI on surgical complications and outcomes in endometrial cancer surgery--an institutional study and systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Effect of body mass index on shifts in ultrasound-based image-guided intensity-modulated radiation therapy for abdominal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Adjuvant therapy for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Sensors of ionizing radiation effects on the immunological microenvironment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Prognostic factors for uterine cancer in reproductive-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Bokhman's dualistic model of endometrial carcinoma. Revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Classification of endometrial carcinoma: more than two types

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Histotype-genotype correlation in 36 high-grade endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer: a validation study of the Gynecologic Oncology Group criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Markers for individualised therapy in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

A clinically applicable molecular-based classification for endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Gr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Use of mutation profiles to refine the classification of endometrial carcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Progestational agents in the treatment of carcinoma of the endometrium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30094

7 January 2021

Identifiers

DOI

10.1002/CNCR.30094

1 reference

7 September 2017

1 reference